PT  - JOURNAL ARTICLE
AU  - MAIMON, OFRA
AU  - NISMAN, BENJAMIN
AU  - BROIER, SHANI
AU  - BEN-DAVID, INNA
AU  - KUZNETZ, ANNA
AU  - GELFAND, YAEL
AU  - MIZRAHI, AVITAL
AU  - PRUS, EUGENIA
AU  - FUCHS, INBAL
AU  - LOTEM, MICHAL
AU  - POPOVTZER, ARON
AU  - KHUTSURAULI, SALOME
AU  - MEIROVITZ, AMICHAY
AU  - NECHUSHTAN, HOVAV
AU  - PERETZ, TAMAR
TI  - The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report
AID  - 10.21873/anticanres.17175
DP  - 2024 Aug 01
TA  - Anticancer Research
PG  - 3543--3550
VI  - 44
IP  - 8
4099  - http://ar.iiarjournals.org/content/44/8/3543.short
4100  - http://ar.iiarjournals.org/content/44/8/3543.full
SO  - Anticancer Res2024 Aug 01; 44
AB  - Background: Current standard treatment for metastatic breast cancer (MBC) involves cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with endocrine therapy, showing potential in enhancing anti-tumor immune responses. Case report: This report details a clinical case of MBC where palbociclib was co-administered with letrozole. The integration of allogeneic tumor vaccination to this treatment led to heightened interferon-γ production, expansion of CD8+ and NK cell populations, and positive delayed-type hypersensitivity reactions, indicating successful development of anti-tumor immunity. The induced production of interferon-γ by tumor vaccination was associated with manageable modulation of sensitivity to palbociclib-letrozole therapy. Administration of the BioNTech/Pfizer Covid-19 vaccine compromised the anti-tumor immune response by reducing cytotoxic cell populations and increasing immunosuppressive cytokine production. The patient undergoing combined treatment achieved a progressive-free survival of 42 months. Conclusion: Incorporating active tumor vaccination with CDK4/6 inhibitor therapy presents a feasible approach for metastatic breast cancer. The precise regulation of the microenvironment emerges as a crucial factor and warrants careful consideration.